In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis

Methods in Molecular Biology

Volumn 1030, Issue , 2013, Pages 59-79

  Zhang, Rumin ^a   Windsor, William T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Binding kinetics; Boceprevir; Drug target residence time; Global progress curve analysis; HCV NS3 protease; Kinetic profiling; Telaprevir

Indexed keywords

BOCEPREVIR; HEPATITIS C VIRUS NS3 PROTEASE INHIBITOR; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CRITICAL MICELLE CONCENTRATION; DISSOCIATION CONSTANT; ENZYMATIC ASSAY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME KINETICS; EXPERIMENTAL DESIGN; IN VITRO STUDY; ISOMERIZATION; NEGATIVE FEEDBACK; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REACTION TIME; STEADY STATE; VIRUS INHIBITION;

ANTIVIRAL AGENTS; ENZYME ASSAYS; HEPACIVIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KINETICS; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84880092262     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-484-5_6     Document Type: Article

References (28)

1. Zhang R, Monsma F (2010) Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs. Expert Opin Drug Discov 5:1023-1029
2. Copeland RA (2010) The dynamics of drugtarget interactions: drug-target residence time and its impact on effi cacy and safety. Expert Opin Drug Discov 5:305-310
3. Lu H, Tonge PJ (2010) Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol 14:467-474
4. Swinney DC (2009) The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Dev 12:31-39
5. Vauquelin G (2010) Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin Drug Discov 5:927-941
6. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739
7. Tummino PJ, Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47:5481-5492
8. Zhang R, Monsma F (2009) The importance of drug-target residence time. Curr Opin Drug Discov Dev 12:488-496
9. Fang Y (2012) Ligand-receptor interaction platforms and their applications for drug discovery. Expert Opin Drug Discov 7:969-988
10. Vauquelin G (2012) Determination of drugreceptor residence time by radioligand binding and functional assays: experimental strategies and physiological relevance. Med Chem Commun 3:645-651
11. Andersson K, Karlsson R, Lofas S et al (2006) Label-free kinetic binding data as a decisive element in drug discovery. Expert Opin Drug Discov 1:439-446
12. Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley., Hoboken, NJ, pp 141-213
13. Kwong AD, Kauffman RS, Hurter P, Mueller P (2011) Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 29:993-1003
14. Njoroge FG, Chen KX, Shih NY, Piwinski JJ (2008) Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 41:50-59
15. Taremi SS, Beyer B, Maher M et al (1998) Construction, expression, and characterization of a novel fully activated recombinant singlechain hepatitis C virus protease. Protein Sci 7:2143-2149
16. Zhang R, Beyer BM, Durkin J et al (1999) A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal Biochem 270:268-275
17. Cha S (1976) Tight-binding inhibitors-III. A new approach for the determination of competition between tight-binding inhibitors and substrates-inhibition of adenosine deaminase by coformycin. Biochem Pharmacol 25: 2695-2702
18. Morrison JF, Walsh CT (1988) The behavior and signifi cance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301
19. Sculley MJ, Morrison JF, Cleland WW (1996) Slow-binding inhibition: the general case. Biochim Biophys Acta 1298:78-86
20. Szedlacsek SE, Duggleby RG (1995) Kinetics of slow and tight-binding inhibitors. Methods Enzymol 249:144-180
21. Williams JW, Morrison JF, Duggleby RG (1979) Methotrexate, a high-affi nity pseudosubstrate of dihydrofolate reductase. Biochemistry 18:2567-2573
22. Murphy DJ (2004) Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. Anal Biochem 327:61-67
23. Copeland RA, Basavapathruni A, Moyer M, Scott MP (2011) Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Anal Biochem 416:206-210
24. Kuzmic P (2008) A steady state mathematical model for stepwise slow-binding reversible enzyme inhibition. Anal Biochem 380:5-12
25. Kuzmic P, Elrod KC, Cregar LM et al (2000) High-throughput screening of enzyme inhibitors: simultaneous determination of tightbinding inhibition constants and enzyme concentration. Anal Biochem 286:45-50
26. Plesner IW, Bulow A, Bols M (2001) Accurate determination of rate constants of very slow, tight-binding competitive inhibitors by numerical solution of differential equations, independently of precise knowledge of the enzyme concentration. Anal Biochem 295:186-193
27. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
28. Yang J, Copeland RA, Lai Z (2009) Defi ning balanced conditions for inhibitor screening assays that target bisubstrate enzymes. J Biomol Screen 14:111-120